MedPath
EMA Product

Dukoral

Product approved by European Medicines Agency (EU)

Basic Information

Dukoral

Regulatory Information

EMEA/H/C/000476

Authorised

April 28, 2004

14

April 6, 2022

Company Information

Sweden

S-105 21 Stockholm

Valneva Sweden AB

Active Substances Detail

recombinant cholera toxin B subunitvibrio cholerae 01

Detailed Information

Therapeutic Indication

### Therapeutic indication Dukoral is indicated for active immunisation against disease caused by Vibrio cholerae serogroup O1 in adults and children from 2 years of age who will be visiting endemic/epidemic areas. The use of Dukoral should be determined on the basis of official recommendations taking into consideration the variability of epidemiology and the risk of contracting disease in different geographical areas and travelling conditions. Dukoral should not replace standard protective measures. In the event of diarrhoea measures of rehydration should be instituted.

Overview Summary

Dukoral is a vaccine that is given by mouth to protect people against cholera, a serious disease that causes severe diarrhoea. It is used in people aged from 2 years who will be visiting areas with high risk of cholera. Cholera is caused by the bacterium Vibrio cholerae (V. cholerae), which is caught from contaminated food or water. Dukoral should be used according to official recommendations, taking into account where cholera occurs and the risk of catching the disease. The vaccine contains 4 different inactivated strains (types) of V. cholerae serotype O1, and part of a toxin from one of these strains as active substances.

© Copyright 2025. All Rights Reserved by MedPath